📰 Therapeutic Vector Evolution News
Page 3 - Therapeutic Vector Evolution News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Therapeutic Vector Evolution. Real-time updates on events, politics, business and more.
May 24, 2023
Interim data to be presented in an oral presentation by Dr. Jennifer L. Taylor-Cousar, MD, MSCS at the 2023 ECFS Annual Meeting in Vienna, Austria on Thursday, June 8, 2023 at 5:00 p.m. CET Company to... | May 24, 2023
May 10, 2023
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual MeetingOn track for completion of enrollment... | May 10, 2023
May 9, 2023
Underwriters’ full exercise of option brings gross proceeds to $138.0 millionEMERYVILLE, Calif., May 09, 2023 -- 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company... | May 9, 2023
May 8, 2023
EMERYVILLE, Calif., May 08, 2023 -- 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large... | May 8, 2023
May 4, 2023
EMERYVILLE, Calif., May 04, 2023 -- 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large... | May 4, 2023
May 2, 2023
The first patient has been dosed in a phase 1/2 clinical trial investigating 4D-150 for the treatment of wet age-related macular degeneration, according to a press release from 4D Molecular Therapeutics.“4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid, which we invented through our proprietary Therapeutic Vector Evolution platform,” David Kirn, MD,
March 28, 2022
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary... | March 28, 2022
October 29, 2021
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing...
October 26, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
October 26, 2021
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the...